IFNG and ovarian carcinoma: Combination therapy induces immune activation probably in a STING-independent manner, including increasing the expression of IFNγ and related immunostimulatory chemokines, enhancing the systemic production of TNFα and IFNγ, and increasing the number of TILs in patients with ovarian cancer.